HC Wainwright Issues Positive Estimate for SANA Earnings

Key Points

• HC Wainwright raised its Q2 2026 EPS estimate for Sana to ($0.12) from ($0.13), maintained a Buy rating and a $7.00 price objective, and issued FY2026–FY2029 EPS forecasts ranging from ($0.52) to ($0.65).
• Sana reported ($0.16) EPS on March 3, missing the ($0.13) consensus, and its stock trades around $3.44 with a market cap near $918 million.
• Analyst opinions are mixed (six Buys, one Hold, one Sell) resulting in an overall Moderate Buy consensus with a $8.20 price target, and institutional investors own roughly 88.23% of the company.

Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) - Equities research analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Sana Biotechnology in a research note issued on Tuesday, April 14th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.12) per share for the quarter, up from their previous estimate of ($0.13). HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Sana Biotechnology's current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Sana Biotechnology's FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.58) EPS, FY2028 earnings at ($0.63) EPS and FY2029 earnings at ($0.65) EPS.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.03).

Other analysts have also issued reports about the company. Zacks Research lowered Sana Biotechnology from a "strong-buy" rating to a "hold" rating in a report on Tuesday, March 3rd. Wedbush boosted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Tuesday. Weiss Ratings restated a "sell (d-)" rating on shares of Sana Biotechnology in a report on Tuesday. Bank of America boosted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company a "buy" rating in a report on Tuesday, January 6th. Finally, Wall Street Zen lowered Sana Biotechnology from a "hold" rating to a "sell" rating in a report on Saturday, February 7th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Sana Biotechnology currently has an average rating of "Moderate Buy" and a consensus price target of $8.20.

Sana Biotechnology Trading Down 1.1%

SANA stock opened at $3.44 on Thursday. The business's 50-day moving average price is $3.48 and its two-hundred day moving average price is $4.13. The firm has a market cap of $918.03 million, a PE ratio of -3.55 and a beta of 2.06. Sana Biotechnology has a 1-year low of $1.53 and a 1-year high of $6.55.

Hedge Funds Weigh In On Sana Biotechnology

Institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. increased its position in Sana Biotechnology by 74.3% during the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock worth $39,000 after buying an additional 4,088 shares during the last quarter. TD Waterhouse Canada Inc. acquired a new position in Sana Biotechnology during the third quarter worth approximately $37,000. LRI Investments LLC acquired a new position in Sana Biotechnology during the fourth quarter worth approximately $41,000. Jacobi Capital Management LLC acquired a new position in Sana Biotechnology during the fourth quarter worth approximately $41,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Sana Biotechnology during the third quarter worth approximately $36,000. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.